Trials / Terminated
TerminatedNCT07000630
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis; A Nonrandomized Controlled Trial
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | 25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks. |
Timeline
- Start date
- 2025-06-20
- Primary completion
- 2025-11-30
- Completion
- 2025-12-01
- First posted
- 2025-06-03
- Last updated
- 2026-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07000630. Inclusion in this directory is not an endorsement.